Cutting-Edge Therapies for Hypertrophic Cardiomyopathy (HCM)

Hypertrophic cardiomyopathy Hypertrophic cardiomyopathy (HCM) is the most common monogenetic cardiovascular disorder occurring in about 1 per 500 people in the general population. Approaches to the treatment of HCM vary considerably depending on how the patient is affected. At Emory Healthcare, we are fortunate to have true experts capable of providing state-of-art therapies which range from genetic counseling or simple life-style adjustments to cardiac transplantation. Patients at risk for sudden cardiac death receive life-saving cardiac defibrillators. Those with drug-refractory symptoms due to obstruction of outflow from the heart receive septal reduction either by open heart surgery or by catheter ablation. The Emory Hypertrophic Cardiomyopathy Center is a regional and national center of excellence capable of addressing the full range of challenges in the patient with HCM.

For more information about programs that make up the Emory Heart & Vascular Center, visit emoryhealthcare.org/heart.

About John Douglas, MD

John Douglas, MDDr. John Douglas is an interventional cardiologist at the Emory Heart & Vascular Center. He is also a Professor of Medicine at Emory University School of Medicine and Director of the Interventional Cardiology Fellowship Program. He is one of the most tenured Emory cardiologists, beginning his career in 1974. He has been recognized in America’s Top Doctors, Atlanta’s Top Doctors and The Best Doctors in America.

Tags: , , ,

Comments are closed.